Search Results

Welchol is indicated as an adjunct to diet and exercise to:

• reduce elevated low-density lipoprotein cholesterol (LDL-C) in patients with primary hyperlipidemia
• reduce LDL-C levels in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia (HeFH)
• improve glycemic control in adults with type 2 diabetes mellitus

• Welchol should not be used for the treatment of type 1 diabetes or for the treatment of diabetic ketoacidosis
• The effect of Welchol on cardiovascular morbidity and mortality has not been determined.
• Welchol has not been studied in type 2 diabetes in combination with a dipeptidyl peptidase-4 inhibitor
• Welchol has not been studied in Fredrickson Type I, III, IV, and V dyslipidemias
• Welchol has not been studied in children younger than 10 years of age or in premenarchal girls